B cells have been identified as a key factor rapidly worsening kidney function in patients with diabetic kidney disease (DKD). According to a study published in the international journal Nature, B cells form tertiary lymphoid structures (TLS) in the kidneys and drive disease prog
2026-05-05
Cytokinetics’ cardiac disease treatment Myqorzo (aficamten) met all primary endpoints at week 36 in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (nHCM), achieving statistical significance. The trial used patient-reported outcomes measured by the KCCQ and improve
2026-05-05
A reinforcement learning-based AI model called 'SynteMol-RL' identified a new antibiotic candidate that reduced bacterial counts by more than 99% in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) infection. The model predicted candidates from approximately 46
2026-05-05
The American Biotech Innovation Alliance (ABIA), comprising 21 U.S. biotech companies and institutions, has officially launched. In response to China’s control of 80% of the active pharmaceutical ingredient (API) supply for antibiotics, ABIA will publish a report addressing regul
2026-05-05
The hospitalization rate for cold-related illnesses, including hypothermia, nearly tripled over the past 25 years, rising sharply from 42 to 123 cases per 100,000 hospitalizations, according to findings. The analysis found that patients with autism, substance use disorders or men
2026-05-05
Viridian’s thyroid eye disease (TED) drug, elegrasibart, met the primary endpoint in a phase 3 trial with a 54% response rate. The self-administered subcutaneous injection, given every 8 weeks, showed a significant difference compared with placebo (15%). The company plans to seek
2026-05-05
Cytokinetics’ Myqorzo achieved both efficacy goals in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM). The ACACIA study found statistically significant improvements in heart failure symptoms and cardiovascular health. If approved by regulators, the drug is ex
2026-05-05
Cytokinetics’ heart disease treatment Myqorzo met both efficacy goals in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (HCM). In the trial, named ACACIA, Myqorzo demonstrated statistically significant improvements in heart failure symptoms and cardiovascular heal
2026-05-05
Anu Pharma has received World Health Organization (WHO) prequalification (PQ) for an active pharmaceutical ingredient (API) used in malaria treatment. With this certification, the company has established itself as a key supplier to global malaria programs that provide WHO essenti
2026-05-05
Global pharmaceutical company Lupin has received approval from the U.S. Food and Drug Administration (FDA) for a generic treatment for urea cycle disorders (UCDs), a market valued at $337 million annually. The approved glycerol phenylbutyrate oral solution, 1.1 g/mL, is bioequiva
2026-05-05
